Tingyan Shi, MD, PhD, of Zhongshan Hospital, Fudan University, discusses study results that showed secondary cytoreductive surgery in selected patients extended progression-free survival and might contribute to long-term survival (Abstract 6001).
Cynthia X. Ma, MD, PhD, of Washington University, discusses results from the ALTERNATE trial, which showed neither fulvestrant nor fulvestrant plus anastrozole significantly improved endocrine-sensitive disease rate compared with anastrozole alone in postmenopausal patients with locally advanced estrogen receptor–positive, HER2-negative breast cancer (Abstract 504).
Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III data from the CONDOR trial, which showed that PSMA-targeted PET scans detected and localized occult disease in most men with biochemically recurrent prostate cancer presenting with negative or equivocal conventional imaging findings (Abstract 5501).
Egbert F. Smit, MD, PhD, of the Netherlands Cancer Institute, discusses interim results from the DESTINY-Lung01 trial of fam-trastuzumab deruxtecan in patients with HER2-mutated metastatic non–small cell lung cancer. The data show clinical activity with high overall response rates and durable responses (Abstract 9504).
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discusses three important studies focusing on newer therapies for patients with recurrent platinum-sensitive, platinum-agnostic, and advanced recurrent ovarian cancers (Abstracts 6003, 6004, and 6005).
Howard A. Burris III, MD, FACP, FASCO, Immediate Past President of ASCO and current Society Board Chair, talks about how the meeting went, with its record-breaking attendance and new format.
